Clinical trial · Interventional
CT Perfusion Scans in Detecting Changes in Blood Flow to the Liver After Portal Vein Embolization
To Evaluate Perfusion Changes to the Liver Following Pre-Operative Portal Vein Embolization for Patients With Liver Cancer
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This trial studies the use of computed tomography (CT) perfusion scans in detecting changes in blood flow to the liver after portal vein embolization in patients with liver cancer. CT perfusion scans use a standard contrast drug given by vein to measure blood flow to the liver. CT perfusion scans may predict the rate and amount of growth of new, healthy tissue on one side of the liver after a portal vein embolization and detect change to the size of the liver tumor as result of the procedure.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Liver and Intrahepatic Bile Duct Carcinoma | Liver Carcinoma | ALIAS | 0.90 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Computed Tomography Perfusion Imaging | Radiation | — | UNRESOLVED |
| Liver Biopsy | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Diagnostic (CT perfusion scans, liver biopsy)
- description
- Prior to PVE, patients undergo CT perfusion scan of the liver and liver biopsy over 15 minutes. Patients undergo a second CT perfusion scan immediately after PVE and a third CT perfusion scan 3-6 weeks post PVE.
- interventionNames
- Radiation: Computed Tomography Perfusion Imaging
- Procedure: Liver Biopsy
Primary outcomes (1)
- measure
- Perfusion changes to the liver following portal vein embolization (PVE)
- timeFrame
- Baseline up to 6 weeks post PVE
- description
- Will assess whether perfusion changes to the liver following PVE correlate with hypertrophy of the future liver remnant (FLR). Perfusion and FLR hypertrophy are two continuous variables. Each patient will serve as his/her own control. Perfusion to the liver (1) before PVE, (2) immediately after PVE, and (3) 3-6 weeks following PVE will be measured and compared. The changes in perfusion will be compared with FLR hypertrophy at the 3-6 week time point to assess correlation.
Secondary outcomes (1)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Patients planned to undergo major liver resection for cancer who need PVE to increase the size of the FLR prior to surgery. * Patients who are able to understand and give consent to participate in the study. Exclusion Criteria: * Pregnant or nursing. * Allergy to iodinated contrast which cannot be safely pre-medicated. * History of severe renal dysfunction (glomerular filtration rate \[GFR\] \< 30 mL/min/1.73 square meters). Patients with a GFR between 30-50 mL/min/1.73 square meters will receive the standard contrast-induced nephropathy prophylaxis at our institution (i.e. N-acetylcysteine and sodium bicarbonate \[150 mEq/L\] in D5W intravenous).
References
Publications (0)
Data not yet available